Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine and Rituximab in Splenic Marginal Zone Lymphoma
NCT02853370Phase 2Completed
- Sponsor
- International Extranodal Lymphoma Study Group
- Start
- Jul 2012
- Primary completion
- Dec 2020
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of bendamustine, rituximab in splenic marginal zone lymphoma (SMZL), sponsored by International Extranodal Lymphoma Study Group. Started Jul 2012; status: completed.
02
Drugs
bendamustinerituximab
03
Conditions
splenic marginal zone lymphoma (SMZL)
Beyond the preview
Go deeper on NCT02853370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02853370.